JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis

  • 0Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA. kjh7vp@uvahealth.org.
Bmc Cancer +

|

November 29, 2024

|

November 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Dabrafenib plus trametinib shows promise for glioma treatment, with higher response rates in low-grade gliomas (LGGs). Favorable outcomes are linked to younger age, BRAF V600 mutation, and prior resection history.

Area Of Science

  • Neuro-oncology
  • Pharmacology
  • Clinical Trials

Background

  • Dabrafenib plus trametinib represents a novel targeted therapy for both low-grade (LGG) and high-grade (HGG) gliomas.
  • Gliomas are primary brain tumors with diverse histological grades and molecular profiles.

Purpose Of The Study

  • To systematically review and meta-analyze the safety and efficacy of dabrafenib plus trametinib in LGG and HGG gliomas.
  • To identify patient subgroups and treatment characteristics associated with improved outcomes.

Main Methods

  • A comprehensive search of PubMed/Medline, Scopus, Embase, and Web of Science databases was conducted.
  • Meta-analyses, sensitivity analyses, publication bias assessment, and meta-regression were performed using R software.
  • Nine studies involving 313 patients were included in the final analysis.

Main Results

  • The pooled objective response rate (ORR) was 47%, with higher partial response (PR) rates and lower progressive disease (PD) rates observed in LGGs.
  • Favorable outcomes in HGGs were associated with younger age, BRAF V600 mutation, longer treatment duration, and prior resection.
  • The pooled discontinuation rate due to adverse events (AE) was 12%.

Conclusions

  • Dabrafenib plus trametinib demonstrates favorable outcomes in glioma patients, particularly in LGGs.
  • Patient factors such as age, BRAF V600 mutation status, and treatment history significantly influence efficacy.
  • This combination therapy offers a promising targeted approach for specific glioma populations.

Keywords: